このページの翻訳は実験的なもので、現在開発中です。お待ちしております

XBiotech 過去の業績

過去基準チェック /06

XBiotechの収益は年間平均-55.3%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 17.7%割合で減少しています。

主要情報

-65.3%

収益成長率

-64.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-28.6%
株主資本利益率	-17.8%
ネット・マージン	n/a
前回の決算情報	30 Jun 2024

Recent updates

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

収支内訳

XBiotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:XBIT 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	0	-35	5	38
31 Mar 24	0	-31	5	36
31 Dec 23	0	-25	5	33
30 Sep 23	0	-23	5	32
30 Jun 23	2	-28	5	32
31 Mar 23	4	-31	6	31
31 Dec 22	4	-33	6	32
30 Sep 22	8	-36	7	33
30 Jun 22	11	-27	8	32
31 Mar 22	14	-20	9	30
31 Dec 21	18	-17	9	28
30 Sep 21	19	-13	12	23
30 Jun 21	25	-12	14	20
31 Mar 21	36	-14	16	13
31 Dec 20	44	-11	18	10
30 Sep 20	39	677	17	16
30 Jun 20	28	673	15	19
31 Mar 20	13	674	10	21
31 Dec 19	0	669	7	24
30 Sep 19	0	-24	5	19
30 Jun 19	0	-23	5	18
31 Mar 19	0	-23	5	17
31 Dec 18	0	-21	5	16
30 Sep 18	0	-22	6	17
30 Jun 18	0	-23	6	17
31 Mar 18	0	-27	7	21
31 Dec 17	0	-33	8	26
30 Sep 17	0	-42	9	34
30 Jun 17	0	-49	10	39
31 Mar 17	0	-53	10	43
31 Dec 16	0	-53	11	42
30 Sep 16	0	-48	9	39
30 Jun 16	0	-47	8	39
31 Mar 16	0	-40	7	32
31 Dec 15	0	-37	6	31
30 Sep 15	0	-32	7	25
30 Jun 15	0	-28	9	19
31 Mar 15	0	-25	7	18
31 Dec 14	0	-22	8	14
30 Sep 14	0	-18	6	12

質の高い収益: XBITは現在利益が出ていません。

利益率の向上: XBITは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: XBITは利益が出ておらず、過去 5 年間で損失は年間55.3%の割合で増加しています。

成長の加速: XBITの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: XBITは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: XBITは現在利益が出ていないため、自己資本利益率 ( -14.69% ) はマイナスです。

XBiotech 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06